THE WOODLANDS, Texas--(BUSINESS WIRE)--Today, Repros Therapeutics Inc. (NasdaqGM:RPRX) received notification from NASDAQ that it has granted the Company the opportunity for an oral hearing to plead its case for an extension of time before delisting associated with the $1 share price requirement per NASDAQ Listing Rule 5550(a)(2). The hearing is scheduled for July 22, 2010.
